Thank revenue commercial it's around product Recall cost first quarter. patients therefore, that I'm reported time recognition the Libmeldy. goods spend and revenue our open some for from color communications like to first you, we treated we've the in prior Bobby. the reviewing I'd going X and performance section financial my the some sales with of from quarter. since to time recognized for
flow be rather than over the paid multiple will upfront from Importantly, these patients years. cash
the payment to the agreements preference to on over payer. be open outcome-based continue We or time of depending
primarily programs for payment opted early These treated an access of product March structure. Libmeldy months and million XXXX. Revenue under XX, upfront X most sales ended for to However, Germany. date payers X the patients was were have France from reimbursed in $X.X first
may in countries. of patient indicative per not ultimately be pricing the revenue the So final those
of Libmeldy. are net worth it's of with primary the COGS the published per that final million for in million sales to spending X $X.X make However, items were price a Cost that and you'll and Germany. up patient, negotiated X.X a about few here period, there is product for it's minutes figure similar note sales
drug the The meaning the the of cost cost first manufacturing, to product produce the for patient. is
The and were of second third royalties, is that previously. amortization noncash is the paid milestones third-party
sales the vector used the in that batches of currently years total and manufacturing Libmeldy. since assumption not use Libmeldy On annual expensed to Royalties were royalties the produced and reasonable forward. The the of in of these approval. to we does future cost that's going in achieve the higher quarter, prior to third lentiviral current net include a be vector those first patients may first item, parties higher cost was XX% of sales as about
revenue the press can quarter first our full from the find financial and in Beyond results you release morning. this Libmeldy COGS,
operating potential touch additional Let the expenses regulatory the focus milestones, March, data on runway including on launch the we there value-creating of in changes and announced a see XXXX milestones while also to benefits in several impact quarter, and me and the Since our our the but end in start U.S. releases. in extend into we to March the those quarter. of will at The restructuring on expect wasn't second approval meaningful maintaining do beginning restructuring. operational the happened Libmeldy
We fund been used to which R&D credit quarter totaling organization have our first tax about and year. from the also $XX quarter program million $X.X took onetime $XXX which the were to million XX, and March tax their in $XX rate net charges included credit, for would are in that $XX operating of refunds cash in Cash million XXXX. Without the quarter is expenses investments of of costs. related burn The for million. restructuring company the during XXXX first certain the roughly termination million, the as about operations,
expect to into XXXX, exiting giving would per closer over quarterly runway operating course to XXXX. $XX I to of the forward, million quarter, year us expenses Going million down the rate our burn come $XX and
partner also therapy proven partnership development go, a bringing that a therapeutic we or business see disease like platform. strategy space might particular in about farming HSC capabilities. think has be many expertise clinical As deal beyond gene and patient We HSCs prevalent opportunities a Orchard's announced populations existing HSC leverage together funding space that set therapy in good targets. disease would for infrastructure bring more commercial indicator in in with Treg state precursor for for a the where we The XXXX, an The and/or could our IP our partners capabilities, than conditions a also ideal knowledge, across XXXX think is an antibodies to or the tissue-specific a using potential just deliver capital have other additional with or monoclonal of platform. gene larger more deals opportunities to could in with idea we of farming the in business BD the commercial but
activities There Looking inflection the forward, the accrue operational this the implemented we of call a throughout commercial pipeline our our are as dedicated with point for stakeholders. for year. and for XXX% exciting business first promise for that, the that Orchard we've and candidates, changes should an at to and balance are We're With at remainder our the of patients, end we're of the therapies of and an the Libmeldy benefit clinical with the pleased research important progress we us to quarter. reality to of benefits and operator our over we to making questions. made I'll turn community the financial
